NCT01579149View on ClinicalTrials.gov

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Healthy Volunteer
Interventions
DRUG

plerixafor

Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),

DRUG

Placebo

Single subcutaneous (SC) dose of placebo

Trial Locations (1)

Unknown

Honolulu

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT01579149 - A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent | Biotech Hunter | Biotech Hunter